Clinical trials: Conjunctiva; Disorder
- Condition Conjunctiva; Disorder
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal
Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
Topical rVA576 for treatment of atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC),and severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC)): a randomised placebo-controlled double masked parallel…
- Conditions
- Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic
- Trial name
- NCT04037891
- Testing
- rVA576
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 12 people
- Sponsor
- AKARI Therapeutics
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Dry Eye, Dry Eye Syndromes
Tear Production by Nasal Neurostimulation Compared to Active Control
This crossover design study evaluates the effectiveness of the Oculeve Intranasal Neurostimulator comparing the effect of intranasal (active) versus extranasal (control) stimulation on tear production as measured by the Jones…
- Conditions
- Dry Eye, Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Trial name
- NCT02970799
- Testing
- Intranasal Neurostimulator
- Volunteers
- 27 people
- Sponsor
- Oculeve, Inc.
Conjunctivitis, Allergic
A Study of ADX-102 in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen…
- Trial name
- NCT03012165
- Testing
- ADX-102 Ophthalmic Drops (0.5%), ADX-102 Ophthalmic Drops (0.1%), Vehicle of ADX-102 Ophthalmic Drops
- Where
- 5 sites in United States
- Volunteers
- 154 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Keratoconjunctivitis Sicca
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
This study will evaluate the efficacy of cyclosporine ophthalmic solution vs. other non-prescription treatments in patients with dry eye disease.
- Trial name
- NCT00717418
- Testing
- cyclosporine ophthalmic emulsion 0.05%, artificial tears
- Where
- United States
- Volunteers
- 781 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT02978183
- Testing
- ST266, Saline (0.9% NaCl)
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Bacterial Conjunctivitis
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis
- Trial name
- NCT00518089
- Testing
- Gatifloxacin 0.5% eye drops
- Where
- 2 sites in United States, India
- Volunteers
- 859 people
- Sponsor
- Allergan
Allergic Conjunctivitis
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic…
- Trial name
- NCT01107405
- Testing
- Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID)
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Efficacy and safety study of bepotastine besilate ophthalmic solution in allergic conjunctivitis
- Trial name
- NCT00586664
- Testing
- Bepreve (bepotastine besilate ophthalmic solution) 1.5%, Bepotastine Besilate Ophthalmic Solution 1.0%
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.
- Trial name
- NCT01479374
- Testing
- AL-4943A ophthalmic solution, AL-4943A vehicle, Olopatadine hydrochloride ophthalmic solution, 0.2%
- Volunteers
- 397 people
- Sponsor
- Alcon Research
Pterygium
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the conjunctiva and grows towards the cornea. It can eventually lead to vision impairment.
- Trial name
- SURPH (NCT03533244)
- Testing
- 0.1% AG-86893 Eye Drops, 0.3% AG-86893 Eye Drops, Vehicle Eye Drops
- Where
- 6 sites in Australia
- Volunteers
- 64 people
- Sponsor
- Allgenesis Biotherapeutics Inc.
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102 during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease.
- Trial name
- NCT05586152
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Invirsa, Inc.
Allergic Conjunctivitis
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the…
- Trial name
- NCT00689078
- Testing
- Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- ORA, Inc.
Keratoconjunctivitis Sicca
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a safety extension enrolling subjects participating in Study OTX-101-2016-001 (NCT02688556)
- Trial name
- NCT02845674
- Testing
- OTX-101 0.09%
- Volunteers
- 258 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Allergic Conjunctivitis
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
This study is being conducted to evaluate the safety of KetoNaph ophthalmic solution in healthy adult subjects and in pediatric subjects with a history or family history of ocular allergy.
- Trial name
- NCT01159015
- Testing
- KetoNaph, Vehicle
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis
Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.
- Trial name
- NCT00705159
- Testing
- loteprednol etabonate and tobramycin, loteprednol etabonate, Tobramycin
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
A Six-Week Safety Study of an Investigational Ophthalmic Solution
The purpose of this study was to evaluate the ocular safety of an investigational ophthalmic solution in subjects 2 years of age and older with asymptomatic eyes when administered once daily in both eyes for up to 6 weeks.
- Trial name
- NCT01698814
- Testing
- AL-4943A Ophthalmic Solution, AL-4943A Ophthalmic Solution Vehicle
- Volunteers
- 518 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Allergic Conjunctivitis
Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.
- Trial name
- NCT01159769
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
- Volunteers
- 215 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
- Trial name
- NCT04050865
- Testing
- Dexamethasone, 0.4mg
- Where
- 6 sites in United States
- Volunteers
- 96 people
- Sponsor
- Ocular Therapeutix, Inc.
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S